5 Comments
 

Don’t think you can necessarily go wrong with either, but I feel most people would lean MS. Exits from both are likely comparable if you want to do something within life science investing, but Lazard only does biopharma M&A. MS would give you exposure to cap markets, and my understanding is their healthcare group also covers other verticals outside biotech too (i.e. digital health) so you’d get broader exposure. MS brand also better broadly speaking if you ever want to transition into industry.

From a culture point-of-view, I think it’s a no brainer in favor of MS. Laz HC culture is infamous, and you’d likely re-recruit fulltime anyways to move to a different healthcare group.

 

Explicabo laboriosam dolores fugit iure id natus. Distinctio minima nobis ex aut molestiae laboriosam pariatur. Veritatis aspernatur eaque facere sint aut ad ex dolore.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”